Market Place
Sourcing Support
BeiGene Receives Positive CHMP Opinions For Trvimbra® Treatment
21 Oct 2024 //
BUSINESSWIRE
Onco360 Selected As Partner For Tevimbra
04 Oct 2024 //
GLOBENEWSWIRE
BeiGene Highlights TEVIMBRA Data In Lung And GI Cancers At ESMO 2024
09 Sep 2024 //
BUSINESSWIRE
Glenmark unit ties up with BeiGene to market cancer drugs in India
21 May 2024 //
MONEYCONTROL
BeiGene`s Tislelizumab Approved in EU for Lung Cancer
23 Apr 2024 //
BUSINESSWIRE
US FDA approves BeiGene`s esophageal cancer therapy
15 Mar 2024 //
REUTERS
BeiGene`s Biologic Tevimbra (tislelizumab) Receives Approval in the U.S.
13 Mar 2024 //
FDA
Akeso Announced the First Patient Dosed in Phase III Trial of Cadonilimab
06 Mar 2024 //
PR NEWSWIRE
BeiGene’s Biologics License Application for TEVIMBRA Accepted by FDA
27 Feb 2024 //
BUSINESSWIRE
BeiGene Receives Positive CHMP Opinion for Tislelizumab
26 Feb 2024 //
BUSINESSWIRE
Asieris will Present For the First Time Interim Analysis Data of Oral APL-1202
25 Jan 2024 //
PR NEWSWIRE
BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy
16 Oct 2023 //
BUSINESSWIRE
Novartis` Tevimbra (tislelizumab) Receives Approval in Europe
10 Oct 2023 //
EMA
Novartis returns PD-1 to BeiGene in another cancer drug divorce
20 Sep 2023 //
FIERCE PHARMA
BeiGene Announces Positive Updates After Regaining Global Rights for TEVIMBRA®
19 Sep 2023 //
PRESS RELEASE
Akeso Announced First Patient Dosed in PIII of Ivonescimab versus Tislelizumab
18 Aug 2023 //
PR NEWSWIRE
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
21 Jul 2023 //
BUSINESSWIRE
Immix Bio Reports 2nd Positive Trial Data Readout in IMX-110 IMMINENT-01 Trial
17 Jul 2023 //
GLOBENEWSWIRE
HiFiBiO Therapeutics Announces First Patient Dosed with HFB200301
23 Jun 2023 //
BUSINESSWIRE
Novartis, BeiGene stage comeback with broader stomach cancer win
21 Apr 2023 //
FIERCE PHARMA
Enlivex Announces Tislelizumab Collaboration, Full Year Financial Results
04 Apr 2023 //
GLOBENEWSWIRE
Enlivex, BeiGene Partner to Evaluate Allocetra/PD-1 Inhibitor Tislelizumab
03 Apr 2023 //
CONTRACT PHARMA
Enlivex Announces Collaboration to Evaluate Combinations of Allocetra & Tislelizumab
03 Apr 2023 //
GLOBENEWSWIRE
BeiGene doubles sales on Brukinsa, tislelizumab strength
27 Feb 2023 //
FIERCE PHARMA
Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110
07 Feb 2023 //
GLOBENEWSWIRE
BeiGene Presents Research from Tislelizumab Global Development Program at ASCO
17 Jan 2023 //
BUSINESSWIRE
BeiGene Announces Acceptance of 12th Regulatory Submission in China,Tislelizumab
31 Dec 2022 //
BUSINESSWIRE
ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Trial
19 Dec 2022 //
GLOBENEWSWIRE
Asieris enrols first subject in Phase II bladder cancer therapy trial
14 Dec 2022 //
CLINICALTRIALSARENA
Immix Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Trial
13 Dec 2022 //
GLOBENEWSWIRE
Asieris Enrolled First Patient for PII Study of Oral APL-1202 with Tislelizumab
12 Dec 2022 //
PRNEWSWIRE
Phanes Therapeutics Announces Supply Agreement with BeiGene to Evaluate PT199
08 Dec 2022 //
PRNEWSWIRE
HiFiBiO Announces Clinical Trial Supply Agreement to Evaluate HFB200603
18 Nov 2022 //
BUSINESSWIRE
BeiGene Announces Data Presentations at ESMO 2022 for Tislelizumab
10 Sep 2022 //
BUSINESSWIRE
Novartis announces tislelizumab demonstrated efficacy and tolerability
10 Sep 2022 //
PRESS RELEASE
HiFiBiO Announces Clinical Trial Supply Agreement to Evaluate HFB200301
15 Aug 2022 //
BUSINESSWIRE
BeiGene reports Phase III tislelizumab data in hepatocellular cancer
10 Aug 2022 //
CLINICAL TRIALS ARENA
BeiGene touts positive PIII data on tislelizumab in aftermath of setbacks at FDA
10 Aug 2022 //
ENDPTS
Novartis shelves an FDA submission for PD-1 tislelizumab
21 Jul 2022 //
FIERCEPHARMA
FDA delays decision on BeiGene`s cancer drug on China COVID curbs
15 Jul 2022 //
REUTERS
New PIII data show Novartis tislelizumab significantly extended median OS
30 Jun 2022 //
GLOBENEWSWIRE
China NMPA Approves Tislelizumab for Recurrent/Metastatic Nasopharyngeal Cancer
10 Jun 2022 //
BUSINESSWIRE
Asieris to present study protocol of APL-1202 with BeiGene`s tislelizumab
27 May 2022 //
PRNEWSWIRE
Novartis data shows promise of its BeiGene-partnered PD-1 drug
27 Apr 2022 //
FIERCEPHARMA
BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial
19 Apr 2022 //
BUSINESSWIRE
BeiGene’s tislelizumab obtains China NMPA approval for oesophageal cancer
19 Apr 2022 //
PHARMACEUTICAL-TECHNOLOGY
China NMPA Approves Tislelizumab in 2L Esophageal Squamous Cell Carcinoma
16 Apr 2022 //
BUSINESSWIRE
BeiGene to Present Results, Biomarker Data on Tislelizumab in Solid Tumors
08 Apr 2022 //
BUSINESSWIRE
EMA Accepts BeiGene`s MAA for Tislelizumab in ESCC and NSCLC
06 Apr 2022 //
BUSINESSWIRE
China NMPA Approves Tislelizumab for Patients with MSI-H or dMMR Solid Tumors
11 Mar 2022 //
BUSINESSWIRE
BeiGene Shows +ve Findings from Phase 3 Trial of Tislelizumab + Chemotherapy
24 Jan 2022 //
BUSINESSWIRE
Novartis oncology chief touts PD-1 global profile
11 Jan 2022 //
FIERCEPHARMA
China NMPA Approves Tislelizumab as Second- or Third-Line Treatment in NSCLC
05 Jan 2022 //
BUSINESSWIRE
World`s 1st Patient Dose Given in Comb. of APL-1202 & Tislelizumab in MIBC
04 Jan 2022 //
ASIAONE
BeiGene Presents Results from Phase 3 Trial of Tislelizumab in RM-NPC
10 Dec 2021 //
BUSINESSWIRE
BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021
02 Dec 2021 //
PRESS RELEASE
BeiGene Announces Inclusion in the China National Reimbursement Drug List
02 Dec 2021 //
BUSINESSWIRE
Zymeworks to Present HERIZON-GEA-01 Pivotal Trial Design and more...
26 Oct 2021 //
BUSINESSWIRE
